1. Scrip
  2. >>Business

Karuna Gears Up To File KarXT, A Schizophrenia ‘Gamechanger’

Free From Serious Side-Effects Of Standard Treatment

 
• By Andrew McConaghie

New CEO Bill Meury said Karuna had plenty of time, money and physician enthusiasm to ensure a US launch in 2024 would be a success.

Brain jigsaw
• Source: Shutterstock

Karuna Therapeutics looks set to be one of biopharma’s rising stars in 2023, with the filing of KarXT, which analysts believe could be a ‘gamechanger’ in treating schizophrenia.

The company’s newly appointed CEO Bill Meury gave a presentation at last week’s J.P

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.